These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36706953)

  • 1. Generic Price Regulation and Drug Expenditures: Evidence From Canada.
    Li Y
    Value Health; 2023 Jun; 26(6):833-840. PubMed ID: 36706953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
    Chen CL; Chen L; Yang WC
    BMC Public Health; 2008 Apr; 8():118. PubMed ID: 18405385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
    Li X; Guh D; Lacaille D; Esdaile J; Anis AH
    Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The short-term impact of Ontario's generic pricing reforms.
    Law MR; Ystma A; Morgan SG
    PLoS One; 2011; 6(7):e23030. PubMed ID: 21829581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
    Yeung K; Dusetzina SB; Basu A
    JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug spending in Canada: recent trends and causes.
    Morgan S
    Med Care; 2004 Jul; 42(7):635-42. PubMed ID: 15213487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?
    Sarnak DO; Squires D; Kuzmak G; Bishop S
    Issue Brief (Commonw Fund); 2017 Oct; 2017():1-14. PubMed ID: 28990747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.
    Morgan SG
    Health Serv Res; 2002 Oct; 37(5):1243-66. PubMed ID: 12479495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Cost Containment and Price Policies on Pharmaceutical Expenditure in South Korea.
    Kim W; Koo H; Lee HJ; Han E
    Int J Health Policy Manag; 2022 Oct; 11(10):2198-2207. PubMed ID: 34814666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of U.S. federal and state generic drug policies on drug use, spending, and patient outcomes: A systematic review.
    Mishuk AU; Fasina I; Qian J
    Res Social Adm Pharm; 2020 Jun; 16(6):736-745. PubMed ID: 31445986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of brand drug discount cards on private insurer, government and patient expenditures.
    Law MR; Chan FKI; Harrison M; Worthington HC
    CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can increases in CHIP copayments reduce program expenditures on prescription drugs?
    Sen B; Blackburn J; Morrisey M; Becker D; Kilgore M; Caldwell C; Menachemi N
    Medicare Medicaid Res Rev; 2014; 4(2):. PubMed ID: 24967148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.